
Walmart, Mattel and other retailers to boost prices as trade war hits shoppers
In an earnings call on Thursday, executives for the retail giant told industry analysts that an increase in prices would be unavoidable in the face of the highest import duties the U.S. has seen since the 1930s.
Goods including vegetables and furniture will see a jump in price, executives said, a trend that will worsen in July when back-to-school shopping begins. Car seats made in China could increase in price by $100, the company said.
'We're wired to keep prices low, but there's a limit to what we can bear, or any retailer for that matter,' Walmart Chief Financial Officer John David Rainey told the Associated Press.
Like other businesses, the company didn't give an outlook for its earnings, reflecting uncertainty in the economy.
Walmart is just the latest retailer and major U.S. company to announce price increases related to the tariffs and trade war with China. Others include consumer products giant Procter & Gamble and Ford, which said it would raise prices on some of its vehicles.
Mattel Inc., the El Segundo-based maker of Barbie and Hot Wheels cars, also announced that it would have to boost prices to offset higher costs from tariffs, prompting a fierce response from Trump, who recently threatened to 'put a 100 percent tariff' on the company's toys.
Trump imposed a universal 10% tariff last month, in addition to a 145% duty on Chinese goods. The latter was cut to 30% in a deal announced this week.
Despite the China deal and several tariff pauses, the cost of producing items such as strollers and spices has rapidly increased since Trump's so-called Liberation Day. The situation for consumers has worsened as businesses have passed production costs down to their customers.
So far, the effects on shoppers have been minimal. Consumer spending rose a scant 0.1% in April, the Commerce Department said Thursday. It's a marked slowdown after a 1.7% increase in March, which economists attributed to panic-purchasing ahead of the tariffs.
At a Walmart in South Gate last week, anxious shoppers took advantage of low prices in anticipation of rising costs.
Leora, who lives near USC and declined to share her last name out of privacy concerns, exited the store with a cart overflowing with toilet paper, paper towels and food items.
'I haven't seen the prices go up yet, but I'm worried,' Leora said. 'That's why I bought so much stuff today.'
Other L.A.-area shoppers said they were already beginning to feel the trickle-down effects of the tariffs.
Artesia resident Amol Chitte was looking to update his home closet storage when he visited Ikea's Carson location in early May. Chitte recently welcomed a baby, he said, and he needed somewhere to store baby clothes and other newborn supplies.
The software engineer said sticker prices were double and even triple the $100 he'd budgeted for the purchase. The items seemed more expensive than they were at this time last year, he said.
'I was surprised how expensive the furniture was,'' he said. 'If I go to a budget store like Walmart, I would find something more reasonable.'
A representative for Ikea did not respond to a request for comment.
Jesper Brodin, chief executive of the Ingka Group, which operates the majority of Ikea stores globally, told CNN in November that 'tariffs make it more difficult for us to maintain the low prices and be affordable for many people, which in the end is our goal.'
Ikea is not the only business struggling with how to respond to rising costs of operation, said Dominick Miserandino, a retail and consumer analyst and CEO of Retail Tech Media Nexus.
These businesses have to do what they can to remain profitable, Miserandino said, but ultimately, raising prices is 'never a good look.'
'If you're raising prices and your competitors are not, the fallout is much worse than the profit gain,' he said.
The reluctance of business owners to hike prices in the absence of certainty regarding Trump's tariffs may explain in part why a spike in inflation has yet to appear in national retail data.
Inflation slowed for the third consecutive month in April, when consumer prices rose 2.3% from a year ago, the Labor Department said Tuesday, although inflation was higher in the Los Angeles region during the same period.
The Consumer Price Index was up 3% in April in the L.A.-Long Beach-Anaheim region, driven mainly by higher costs for housing, medical care and food and beverages, according to Labor Department data examined by The Times.
Manisha Goel, an associate professor of economics at Pomona College, attributed the discrepancy to California's housing crisis, which has driven up property values and thereby boosted regional inflation.
But the relatively modest inflation rates aren't expected to last.
Economists said consumers in Southern California can count on steeper price increases on a range of products — dolls, chocolate,household appliances — in the coming months as the full effects of Trump tariffs take effect.
Niree Kodaverdian, a research manager at L.A. economics consulting firm Beacon Economics said that products with imported parts such as electronics will rise in price most quickly, whereas 'for things that we have a lot of inventory for, we're not going to see price effects right away.'
The researcher also noted that CPI data takes into account a high number of non-imported products, such as airplane tickets.
'The CPI is not necessarily putting extra weights on import-heavy products that consumers are buying,' Kodaverdian said, so the data could be underplaying the impact of the tariffs.
Further, she said, businesses may be holding out on increasing prices until they know the tariffs are here to stay.
Lee Ohanian, an economics professor at UCLA, suspects the U.S. will be able to reach agreements with other countries to keep potential tariff disruptions at a minimum.
'I'm optimistic that this is getting all worked out,' Ohanian said, adding that 'everybody loses in a tariff war, and other countries are relatively bigger losers from this than we are.'
'The best-case scenario is that the tariff war is resolved and that we don't see a burst of inflation in May,' the economist said. If not, he projected the price hikes would be visible in consumer data by June.
Thus far, it's been difficult to gauge the impacts of the tariffs on prices, Ohanian said, but California seems to be hurting disproportionately because of its high property prices and relatively higher-priced groceries.
CPI data showed meat products such as sirloin steak and sliced bacon were more expensive in the western United States, compared to the country as a whole, in April. The higher sticker prices could be a result of California's high food standards and humane animal requirements, Ohanian said.
As American consumers anticipate steep price hikes on essentials and discretionary goods due to the tariffs, their expectations for the future are at a 13-year low, according to the Conference Board's Consumer Confidence Index.
Consumer confidence has seen similar — albeit not quite as severe — lows before, especially in periods of global turmoil, said Stephanie Tully, an associate professor of marketing at USC's Marshall School of Business.
During the COVID-19 pandemic, American consumer confidence saw its steepest drop since the 2008 recession as unemployment and market volatility rose while household income and consumer spending fell. Public sentiment recovered relatively quickly, even despite high inflation, but Tully doesn't expect that to happen this time around.
'In the past, people had more faith that governments and other systems were working to alleviate those things as quickly as possible,' Tully said. Now, with the government contributing to the instability, they don't know when or from whom to expect relief.
Consumers are coping via some common money-saving behaviors, the researcher said, such as shopping at budget stores or eating out less.
Foot traffic at warehouse stores increased in the weeks before Trump's tariffs went into effect, and again when reciprocal tariffs were poised to hit before a 90-day pause, according to recent data from analytics platform Placer.ai.
But without income increases to counter rising costs or any sense of permanence to the tariffs causing them, people may struggle to adapt to their new financial realities.
'Those consumers are going to be feeling [the strain] for years and years to come, probably without really getting used to it,' Tully said.
The Associated Press contributed to this report.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


Business Insider
38 minutes ago
- Business Insider
4 Economic Events That Could Affect Your Portfolio This Week, July 14-18, 2025
Stock indexes fell on Friday, reversing mid‑week gains and closing in the red, as the tariff theme came back to haunt investor sentiment. The S&P 500 (SPX) was down 0.31% for the week, while the Nasdaq-100 (NDX) declined by 0.38% and the Dow Jones Industrial Average (DJIA) dropped 1.02%. Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week. President Trump imposed 35% tariffs on Canadian imports not covered under the U.S.-Mexico-Canada agreement (USMCA). Before that, the president announced new tariffs – ranging from 20% to 50% – on more than 20 trading partners, scheduled for August 1 unless trade deals are reached sooner. The 50% tariff on copper imports, announced earlier in the week, also kept investors worried about the prospect of rising prices for industrial products. Another point of concern was the ongoing trade negotiations with the EU, with markets hoping for an agreement after both sides signaled progress. However, the deal apparently fell through, with the president on Saturday announcing a 30% levy on all imports from the bloc, as well as on goods arriving from Mexico. Although tariffs have had limited impact on inflation thus far, that could change down the road. Thus far, the levies have mostly been absorbed by the supply chain or avoided through stockpiling ahead of implementation. If tariffs continue to ramp up, they will ultimately have to be passed on to consumers, as many industries don't have wide enough profit margins to fully absorb them. The extent to which consumers will bear the tariffs is uncertain because supply chain dynamics are complex – but it's safe to presume that inflation may drift slightly higher over the months ahead. While the tariffs – at least at their announced levels – could have some stagflationary effects by depressing growth and driving up inflation, other factors could counter this. Most economists and analysts agree that the newly approved 'One Big Beautiful Bill' (OBBB) fiscal package would provide a modest boost to U.S. growth. While estimates vary, the baseline projection from the Congressional Budget Office (CBO) is that the OBBB will add an average of 0.5% to annual GDP growth over the next decade, with the largest boost – about 0.9% – coming next year. The growth would stem from deregulation, tax breaks, and business incentives, boosting jobs and investment. With the Fed eventually easing, the U.S. economy may see a meaningful boost in the next couple of years despite the tariffs. Four Economic Events Here are four key economic events that could affect your portfolio this week. For a full listing of additional economic reports, check out the TipRanks Economic Calendar. » June CPI and CPI ex. Food and Energy (Core CPI) – Tuesday, 07/15 – The Consumer Price Index (CPI) is one of two key measures of inflation (the other being the Personal Consumption Expenditures index, or PCE). Policymakers, businesses, and consumers closely monitor the CPI, as it reflects price trends across the economy, shapes consumer spending and business sentiment, and directly influences the Federal Reserve's interest rate decisions. » June Producer Price Index (PPI) and PPI ex. Food and Energy – Wednesday, 07/16 – This report reflects input costs for producers and manufacturers. Since the PPI measures the cost of producing consumer goods – which ultimately affects retail prices – it is viewed as a leading indicator of inflationary pressures. As such, it often foreshadows the following month's CPI and plays a critical role in shaping inflation expectations among policymakers. » June Retail Sales – Thursday, 07/17 – This report measures how much consumers are spending on durable and non-durable goods. Retail Sales is a leading indicator of economic health, offering insight into the current quarter's growth and the inflationary pressures stemming from consumer demand. » July Michigan Consumer Sentiment Index and UoM 5-year Inflation Expectations (preliminary) – Friday, 07/18 – These reports summarize the findings of a monthly survey measuring consumer confidence and long-term inflation expectations in the U.S. Consumer confidence directly affects spending, which accounts for roughly 70% of U.S. GDP. The inflation expectations component is also factored into the Federal Reserve's Index of Inflation Expectations.


Business Insider
39 minutes ago
- Business Insider
The Week That Was, The Week Ahead: Macro & Markets, July 13, 2025
Everything to Know about Macro and Markets Stock indexes fell on Friday, reversing mid‑week gains and closing in the red, as the tariff theme came back to haunt investor sentiment. The S&P 500 (SPX) was down 0.31% for the week, while the Nasdaq-100 (NDX) declined by 0.38% and the Dow Jones Industrial Average (DJIA) dropped 1.02%. Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week. The S&P 500 and the tech-heavy Nasdaq100 hit record highs on Thursday, driven by Nvidia and other tech leaders, while the DJIA came close to its prior all-time high. However, Wall Street's positive momentum came under pressure Friday as tariffs once again became the hot topic of conversation and investor nervousness spiked ahead of the first act of the Q2 earnings season, set to begin this week. Trade War Reloaded President Trump imposed 35% tariffs on Canadian imports not covered under the U.S.-Mexico-Canada agreement (USMCA). Before that, the president announced new tariffs – ranging from 20% to 50% – on more than 20 trading partners, scheduled for August 1 unless trade deals are reached sooner. The 50% tariff on copper imports, announced earlier in the week, also kept investors worried about the prospect of rising prices for industrial products. Another point of concern was the ongoing trade negotiations with the European Union, with markets hoping for an agreement after both sides signaled progress. However, the deal apparently fell through, with the president on Saturday announcing a 30% levy on all imports from the bloc, as well as on goods arriving from Mexico. In a preemptive warning, the president cautioned the levied countries not to retaliate, as that would trigger additional tit-for-tat increases on top of the 30% tariffs. Due to these developments, futures are flashing red for Monday's market open. While the renewed tariff rhetoric pushed the indexes slightly down from their peaks, the reaction was incomparably milder than in April – and much weaker than any other subsequent trade-related dip since then. With the economy chugging along and large companies reporting better than expected earnings, the tariff theme has seemingly transformed into a 'new normal' of elevated trade anxiety, keeping a lid on otherwise exuberant stock market activity. Meanwhile, the tariff windfall is already here, with the Treasury Department reporting a record $26.6 billion in customs duties collected in June, producing a surprise $27 billion budget surplus for the month. Treasury Secretary Scott Bessent recently stated that the U.S. could collect up to $300 billion in tariff revenue by the end of 2025 as Trump's trade policies take full effect. Economists expect tariff revenues to remain elevated for several years, with estimates ranging from $2.2 trillion to $2.8 trillion over the next decade if current policies persist. If that's the case, it could reduce federal borrowing, cap the rise in national debt, and help service existing interest obligations. Profits, Rates and Risks Investors are now awaiting the official opening of earnings season, with the focus on how Trump's tariff saga has affected major U.S. companies. At the moment, analysts don't expect large earnings growth outside of the tech sector, but the few names that have reported so far suggest forecasts may have been too conservative. With tariff headlines weighing on sentiment for much of Q2, analysts may have overestimated their negative short-term impact on the corporate sector. On the other hand, if results disappoint, it could call pricing into question – especially if analysts' estimates for Q3 and Q4 earnings don't rise. Although tariffs have had limited impact on inflation thus far, that could change down the road. Thus far, the levies have mostly been absorbed by the supply chain or avoided through stockpiling ahead of implementation. If tariffs continue to ramp up, they will ultimately have to be passed on to consumers, as many industries don't have wide enough profit margins to fully absorb them. The extent to which consumers will bear the tariffs is uncertain because supply chain dynamics are complex – but it's safe to presume that inflation may drift slightly higher over the months ahead. The Federal Reserve's June minutes showed policymakers are at odds about the inflation threat and the direction of monetary policy. Although the majority is leaning towards a continued 'wait and see' approach, some committee members are now open to cutting rates as soon as this month, while others don't anticipate cutting rates at all in 2025. While the tariffs – at least at their announced levels – could have some stagflationary effects by depressing growth and driving up inflation, other factors could counter this. Most economists and analysts agree that the newly approved 'One Big Beautiful Bill' (OBBB) fiscal package would provide a modest boost to U.S. growth. While estimates vary, the baseline projection from the Congressional Budget Office (CBO) is that the OBBB will add an average of 0.5% to annual GDP growth over the next decade, with the largest boost – about 0.9% – coming next year. The growth would stem from deregulation, tax breaks, and business incentives, boosting jobs and investment. With the Fed eventually easing, the U.S. economy may see a meaningful boost in the next couple of years despite the tariffs. Stocks That Made the News ▣ Nvidia (NVDA) saw its market cap rise above $4 trillion on Thursday, becoming the first company ever to reach this milestone. The company's valuation has surged amid investor enthusiasm for AI, increasing eightfold from about $500 billion in 2021. The AI poster child continued to climb on Friday, bucking the market trend and marking another all‑time high. ▣ PayPal (PYPL) shares dropped following reports that JPMorgan Chase (JPM) plans to begin charging financial technology companies for access to customer data. According to a Bloomberg report, JPM has sent pricing sheets to data aggregators – intermediaries connecting banks and fintechs – outlining new fees for access to customer account data. The fees vary by use case, with payment‑focused firms like PayPal facing higher charges. The move from the largest U.S. bank could disrupt the business models of payment apps that rely on free access to customer data to process transactions. Block, Visa, and Mastercard also saw their shares negatively affected by the report. ▣ Delta Air Lines (DAL) soared after reporting impressive earnings performance in Q2, provided a better-than-expected Q3 outlook, and raised dividends. ▣ Levi Strauss & Co (LEVI) was another winner last week, surging by over 12% as its second quarter revenue and earnings topped analyst expectations. The apparel company also lifted its full-year revenue and profit forecasts. ▣ Kraft Heinz (KHC) saw its shares jump at the end of the week on reports that the company is preparing a restructuring plan that could involve spinning off a significant portion of its grocery business. News of the potential break‑up of KHC came a day after cereal maker WK Kellogg (KLG) soared over 30% following its announced acquisition by Italian sweets company The Ferrero Group. ▣ Autodesk (ADSK) was among the worst‑performing stocks in the S&P 500 last week, dropping more than 11% after reports that the design software giant is exploring a potential acquisition of rival PTC, Inc. (PTC). PTC, which surged about 10% last week and now has a market cap of roughly $21.5 billion, has also attracted interest from other potential buyers. The negative investor reaction suggests concern over the financial implications of such a large acquisition for ADSK. Upcoming Earnings and Dividend Announcements The Q2 2025 earnings season is about to begin, with many notable releases scheduled for this week. The season will officially open with reports from several of the largest U.S. financial and insurance companies: JPMorgan Chase (JPM), Citigroup (C), Wells Fargo (WFC), BlackRock (BLK), Bank of New York Mellon (BK), Bank of America (BAC), Goldman Sachs Group (GS), Morgan Stanley (MS), PNC Financial (PNC), Charles Schwab (SCHW), Progressive (PGR), Interactive Brokers (IBKR), Travelers Companies (TRV), and American Express (AXP).
Yahoo
40 minutes ago
- Yahoo
Raymond James Predicts Up to ~760% Surge for These 2 ‘Strong Buy' Stocks
With the summer of 2025 in full swing, all eyes are once again on President Trump's trade moves. Over the past week, Trump has announced a sweeping series of tariff hikes: a 35% tariff on most Canadian imports, new 30% tariffs targeting goods from both the European Union and Mexico, and a 50% tariff on copper imports from Brazil. He's also warned that unless new trade agreements are reached soon, even broader tariff increases could kick in for other major trading partners as early as August 1. Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week. Naturally, all this has stirred up some uncertainty – especially for investors trying to read the tea leaves on inflation, supply chains, and overall market direction. And yet, Raymond James CIO Larry Adam sees plenty of reason for optimism when looking at the bigger picture. 'For investors, market ups and downs are nothing new. Despite interim setbacks, the S&P 500 has delivered a robust average annual return of ~11% since 1985. Bull markets historically last six times longer than bear markets and produce returns five times more powerful. The takeaway? Stay focused on the long term,' Adam notes. That long-term perspective leads to a clear track, and Adam elaborates on it, saying, 'We continue to favor U.S. equities, where the outlook remains brighter… We expect two rate cuts by year end and two more in 2026, helping growth pick up to 1.5% next year. Trump's 'One Big Beautiful Bill' could also provide a modest boost, even if it adds to the deficit.' Against this backdrop, Raymond James analysts have zeroed in on two stocks they believe are set for substantial growth in the coming year – including one with a potential upside as high as 760%. As if that weren't compelling enough, both names also earn a Strong Buy rating from the analyst consensus, according to the TipRanks database. Let's break down what's behind the bullish sentiment. Achieve Life Sciences (ACHV) We'll start with a stock that is bursting with upside potential. Achieve Life Sciences is both a biopharmaceutical company and a penny stock – two niches known for their ability to deliver outsized returns. Central to the company's growth story is its lead program: developing treatments for nicotine dependence. Nicotine, the key addictive ingredient in tobacco products, has been connected to multiple health problems, including recurrent headaches, high blood pressure, dangerous blood clotting, sleep disorders, and changes in heart rhythm. The most common way that people satisfy their nicotine cravings is through smoking, which brings along its own array of health issues, from COPD to various cancers. This isn't just a health challenge – it's a massive market opportunity. There are 29 million smokers in the US alone, some 16 million Americans living with smoking-related illnesses, and globally, about 8 million smoking-related deaths each year. Achieve is targeting the problem with the development of cytisinicline, a naturally derived drug candidate designed to reduce withdrawal symptoms and make it easier to quit smoking or vaping. What sets cytisinicline apart is its robust clinical profile. The drug has delivered strong Phase 3 data on smoking cessation, with a favorable safety record to match. In the ORCA-2 and ORCA-3 trials, cytisinicline consistently produced statistically significant improvements in abstinence rates versus placebo. In ORCA-3, 30.3% of participants in the 12-week arm achieved continuous abstinence during weeks 9 to 12, compared to 9.4% with placebo, and about 20.5% remained abstinent through week 24 versus 4.2% for placebo. The safety profile was favorable, with mostly mild to moderate side effects and no treatment-related serious adverse events. These findings were reinforced by the ORCA-OL trial, where the independent DSMC's third safety review identified no concerns with long-term cytisinicline use. Now, Achieve is gearing up for the next phase: FDA approval and commercial launch. At the end of June, the company submitted a New Drug Application (NDA) to the FDA. If approved, cytisinicline will become the first FDA-approved drug therapy for nicotine addiction in the past two decades. To support its commercialization efforts, Achieve recently announced a strategic partnership with Omnicom and has raised about $45 million. Moreover, Achieve is not stopping with traditional smokers. The company is advancing cytisinicline as a potential treatment for nicotine dependence in e-cigarette users as well. In the Phase 2 ORCA-V1 trial, cytisinicline produced higher quit rates than placebo among individuals seeking to quit vaping, with no serious adverse events reported. Following these results, Achieve held an end-of-Phase 2 meeting with the FDA and reached agreement on the design of a pivotal Phase 3 trial for vaping cessation. With that green light, the company plans to kick off the ORCA-V2 Phase 3 study in the first half of 2026. Put it all together – the compelling data, the unmet need, the imminent FDA milestone, and a bargain-bin $2.32 share price – and it's no wonder Raymond James analyst Gary Nachman thinks now is the time to get in on the action. 'Our Strong Buy rating is supported by a significant unmet need still in the [nicotine addiction] market that is a major global public health concern, with current options resulting in very low quit rates. Cytisinicline has a compelling clinical profile with strong Phase 2/3 data. Cytisinicline shows high smoking cessation quit rates and a favorable safety profile compared to PFE's Chantix (peak sales $1.1B) that is now generic. Cytisinicline has a proven mechanism that is similar to Chantix, but is naturally derived and more selective resulting in fewer AEs, has 50+ years of safe use in E. Europe, and now a submitted NDA with a de-risked regulatory pathway,' Nachman opined. 'There is a large opportunity in smoking cessation that is ripe for the taking and an expanded partnership with Omnicom should help with the US launch, and potentially big upside from vaping as well… A partnership/acquisition to maximize value is possible,' the analyst added. All of this helps explain Nachman's Strong Buy rating on ACHV, which comes with a $20 price target. If his thesis plays out, investors could be looking at a whopping ~760% gain over the next 12 months. (To watch Nachman's track record, click here) And it's not just Nachman who sees big upside here. The broader analyst community is similarly upbeat: in the past 3 months, ACHV has picked up 4 Buy ratings with no Holds or Sells, earning it a consensus Strong Buy status on Wall Street. Meanwhile, the average price target of $15.25 points to a 557% upside from current levels. (See ACHV stock forecast) Avidity Biosciences (RNA) The next stock catching Raymond James' attention is Avidity Biosciences, a clinical-stage biotech firm aiming to develop a new class of RNA therapeutics – drug candidates designed to tackle the root genetic causes behind a variety of serious diseases. The company is building its pipeline using its proprietary Antibody Oligonucleotide Conjugates platform, or AOC. This platform blends the targeting abilities of monoclonal antibodies with the gene-silencing power of oligonucleotide therapies, creating agents that can home in on disease drivers at the genetic level with notable selectivity and precision. Through this approach, Avidity aims to address conditions that have long eluded effective treatment. At present, the company's primary targets are skeletal muscle diseases, especially within the muscular dystrophy class. Avidity has developed a robust research pipeline, which includes three lead drug candidates that are advancing through clinical trials. These three programs – Del-zota, Del-desiran, and Del-brax – are each aimed at specific muscle disorders: Duchenne muscular dystrophy (DMD), myotonic dystrophy type 1 (DM1), and facioscapulohumeral muscular dystrophy (FSHD), respectively. Each of these candidates has shown solid progress. Del-zota, Avidity's program for Duchenne muscular dystrophy, has demonstrated strong increases in exon skipping and dystrophin production, along with an encouraging safety profile. Based on these results, the company expects to submit its first Biologics License Application (BLA) for del-zota by year-end. Meanwhile, del-desiran has delivered impressive data in early clinical trials, with patients experiencing not only reductions in toxic RNA but also meaningful signs of functional improvement. These encouraging results have been further supported by the ongoing MARINA-OLE extension study, which continues to show sustained benefit with longer-term treatment. On the strength of these findings, the program advanced into the pivotal Phase 3 HARBOR trial. The company previously noted that enrollment would be completed by mid-2025, setting the stage for comprehensive data readouts in the first half of 2026. Rounding out the pipeline, the del‑brax program for FSHD is also advancing steadily. Initial data from the FORTITUDE study demonstrated significant reductions in DUX4 gene expression, and with an FDA‑validated accelerated approval pathway now in place, Avidity launched the pivotal FORWARD Phase 3 trial. This global, 18‑month, randomized, placebo‑controlled study is expected to deliver topline results by H2 2026. With all three programs advancing toward key clinical and regulatory milestones, Raymond James analyst Martin Auster sees strong prospects for success here. 'We have high conviction in del-zota (DMD44) to become the first approved drug from Avidity's antibody oligonucleotide conjugate (AOC) platform. Del-desiran (DM1) has been derisked through Ph1/2 biomarker and functional data, and a positive Ph 3 outcome in ~H1 2026 could be transformative for Avidity given del-desiran's first-mover potential and a large DM1 market opportunity (~$5B+ TAM). Del-brax has an even larger potential first-mover advantage in FSHD (opportunity for a strong competitive moat); we project accelerated approval in 2027 supported by cDUX biomarker data and 12-month placebo-controlled functional data,' Auster stated. Auster's high conviction is reflected in his Strong Buy rating on RNA and a $65 price target, which suggests a potential 107% upside from current levels. (To watch Auster's track record, click here) That's far from the only upbeat take on this stock. RNA enjoys a Strong Buy consensus, based on 18 recent analyst ratings – with 17 Buys and just a single Hold. At its current price of $31.45, the stock's average target price of $64.44 suggests RNA could surge ~105% in value over the next year. (See RNA stock forecast) To find good ideas for stocks trading at attractive valuations, visit TipRanks' Best Stocks to Buy, a tool that unites all of TipRanks' equity insights. Disclaimer: The opinions expressed in this article are solely those of the featured analysts. The content is intended to be used for informational purposes only. It is very important to do your own analysis before making any investment. Disclaimer & DisclosureReport an Issue Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data